The mesenchymal stem cells in multiple sclerosis (MSCIMS) trial protocol and baseline cohort characteristics: an open-label pre-test: post-test study with blinded outcome assessments

BACKGROUND: No treatments are currently available that slow, stop, or reverse disease progression in established multiple sclerosis (MS). The Mesenchymal Stem Cells in Multiple Sclerosis (MSCIMS) trial tests the safety and feasibility of treatment with a candidate cell-based therapy, and will inform...

Descripción completa

Detalles Bibliográficos
Autores principales: Connick, Peter, Kolappan, Madhan, Patani, Rickie, Scott, Michael A, Crawley, Charles, He, Xiao-Ling, Richardson, Karen, Barber, Kelly, Webber, Daniel J, Wheeler-Kingshott, Claudia AM, Tozer, Daniel J, Samson, Rebecca S, Thomas, David L, Du, Ming-Qing, Luan, Shi L, Michell, Andrew W, Altmann, Daniel R, Thompson, Alan J, Miller, David H, Compston, Alastair, Chandran, Siddharthan
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2011
Materias:
Methodology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3059276/
https://www.ncbi.nlm.nih.gov/pubmed/21366911
http://dx.doi.org/10.1186/1745-6215-12-62

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3059276/
https://www.ncbi.nlm.nih.gov/pubmed/21366911
http://dx.doi.org/10.1186/1745-6215-12-62

Ejemplares similares